NIH Public Access Author Manuscript Psychopharmacology (Berl). Author manuscript; available in PMC 2012 February 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Psychopharmacology (Berl). 2011 February ; 213(2-3): 403±412. doi:10.1007/s00213-010-1984-7. Phospholipase C, Ca2+, and calmodulin signaling are required for 5-HT2A receptor-mediated transamidation of Rac1 by transglutaminase Ying Dai, Neuroscience Program, Loyola University, School of Medicine, Maywood, IL, USA; and Department of Pharmacology and Toxicology, University of Kansas, School of Pharmacy, 1251 Wescoe Hall Drive, Lawrence, KS 66045, USA Nichole L. Dudek, Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, School of Medicine, Maywood, IL, USA Qian Li, and Department of Pharmacology and Toxicology, University of Kansas, School of Pharmacy, 1251 Wescoe Hall Drive, Lawrence, KS 66045, USA Nancy A. Muma Department of Pharmacology and Toxicology, University of Kansas, School of Pharmacy, 1251 Wescoe Hall Drive, Lawrence, KS 66045, USA Nancy A. Muma:
[email protected] Abstract Rationale—Serotonin and especially serotonin 2A (5-HT2A) receptor signaling are important in the etiology and treatment of schizophrenia and affective disorders. We previously reported a novel 5-HT2A receptor effector, increased transglutaminase (TGase)-catalyzed transamidation, and activation of the small G protein Rac1 in A1A1v cells, a rat embryonic cortical cell line. Objectives—In this study, we explore the signaling pathway involved in 5-HT2A receptor- mediated Rac1 transamidation. Methods—A1A1v cells were pretreated with pharmacological inhibitors of phospholipase C (PLC) or calmodulin (CaM), and then stimulated by the 5-HT2A receptor agonist, 2,5- dimethoxy-4-iodoamphetamine (DOI).